-
NEJM: Should patients with untreated advanced melanoma be treated with riralimumab-nivolumab combination or nivolumab alone?
Time of Update: 2022-01-23
In patients with previously untreated metastatic or unresectable melanoma, inhibition of the two immune checkpoints, LAG-3 and PD-1, resulted in a greater benefit in progression-free survival than inhibition of PD-1 alone .
-
Front Oncol: Differences in clinical characteristics and clinical prognosis of patients with non-metastatic non-clear cell renal cell carcinoma (non-ccRCC)
Time of Update: 2022-01-23
Non-clear cell renal cell carcinoma (non-ccRCC) includes histologically and molecularly distinct subtypes, such as papillary, chromophobe, collecting duct, and sarcomatoid RCC, with an incidence of 20% to 25% .
-
Clin Cancer Res: The SYSUCC-002 study by Professor Zhongyu Yuan Zhongyu's team confirms that first-line trastuzumab + endocrine therapy is non-inferior to trastuzumab + chemotherapy in patients with HR+HER2+ metastatic breast cancer
Time of Update: 2022-01-23
AEsIn conclusion, the SYSUCC-002 study confirmed that first-line trastuzumab + endocrine therapy was non-inferior to trastuzumab + chemotherapy in patients with HR+HER2+ metastatic breast cancer .
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).
-
Int J Urol: Impact of neoadjuvant chemotherapy on survival and recurrence patterns in patients after robotic-assisted radical cystectomy
Time of Update: 2022-01-23
A Phase III randomized clinical trial SWOG-8710 demonstrates the benefit of NAC iMIBC in which MVAC improves OS A phase III randomized clinical trial SWOG-8710 demonstrates the benefit of NAC iMIBC in which MVAC improves OSRecently, researchers from the United States published an article in "Int J Urol" to analyze the effect of neoadjuvant chemotherapy on the survival and recurrence patterns of patients with muscle-invasive bladder cancer after robotic-assisted radical cystectomy .
-
Cell Reports: Nanoparticle-assisted CRISPR gene editing of vascular endothelium for the first time
Time of Update: 2022-01-23
On January 4, 2022, You-Yang Zhao's team at Northwestern University Feinberg School of Medicine published a paper entitled: Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA in Cell Reports, a sub-journal of Cell.
-
Eur Urol Focus: Is urodynamics required to screen suitable candidates for prostate surgery with lower urinary tract symptoms?
Time of Update: 2022-01-23
In an exploratory analysis of the UPSTREAM trial, researchers from the United Kingdom, published in the journal Eur Urol Focus , investigated routine diagnostic and urodynamic measurements associated with treatment decisions and outcomes .
-
Oral Dis: Measuring LDH in saliva can be a useful method for screening for oral cancer and potentially malignant diseases of the oral cavity
Time of Update: 2022-01-23
A study published in Oral Dis evaluated whether salivary lactate dehydrogenase (LDH) levels were increased in patients with oral cancer (OC) or underlying oral malignancy (OPMD) compared with healthy controls (CG) .
-
NEJM: The fastest ever!
Time of Update: 2022-01-23
A research team has developed a new ultra-fast genome sequencing method for diagnosing rare genetic diseases that takes an average of 8 hours, unprecedented in standard clinical care .
-
Int J Urol: Which is better between percutaneous ablation and minimally invasive partial nephrectomy in the treatment of cT1a renal tumors?
Time of Update: 2022-01-23
Recently, researchers from Italy published an article in the journal Int J Urol comparing the oncological outcomes of partial nephrectomy and local tumor ablation in patients with T1 renal masses .
-
BMC Cancer: Western real-world data adds evidence for the efficacy of immune checkpoint inhibitors in previously treated patients with metastatic gastric cancer
Time of Update: 2022-01-23
Therefore, a multicenter retrospective real-world study was carried out abroad to evaluate the efficacy and safety of immune checkpoint inhibitors in Western patients with previously treated metastatic gastric cancer .
-
Ther Adv Med Oncol: A domestic multicenter head-to-head phase III study found that the second-line FOLFIRI regimen was not superior to single-agent irinotecan therapy in patients with metastatic colorectal cancer, but increased toxicity
Time of Update: 2022-01-23
The study is the first head-to-head study and found that second-line single-agent irinotecan achieved similar PFS, OS and ORR as FOLFIRI in patients with mCRC who failed first-line XELOX/FOLFOX regimens, with less toxicity .
-
Liver Cancer: Real-World Efficacy of Lenvatinib in Hepatocellular Carcinoma: A Retrospective Multicenter Study (ELEVATOR)
Time of Update: 2022-01-23
Lenvatinib showed a higher response rate in patients with better liver function (ORR ALBI grade 1: 31.
Lenvatinib showed a higher response rate in patients with better liver function (ORR ALBI grade 1: 31.
-
JAMA Dermatol: Prevalence, incidence and cancer risk in patients with psoriasis and psoriatic arthritis
Time of Update: 2022-01-23
A study published today in JAMA Dermatol assessed cancer associations and risk in patients with psoriasis or psoriatic arthritis, including the risk of specific cancer subtypes .
The primary outcome was cancer (overall and specific subtypes), as measured by cancer prevalence, incidence, and risk estimates in patients with psoriasis or psoriatic arthritis .
-
Science Immunology: Peng Hua/Fu Yangxin collaborate to develop a new generation of high-efficiency, low-toxicity tumor-specific IL-12 prodrugs
Time of Update: 2022-01-23
On January 7, 2022, Peng Hua's team from the Institute of Biophysics, Chinese Academy of Sciences and Fu Yangxin's team from the University of Texas Southwestern Medical Center published a paper entitled: A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells in the journal Science Immunology Research paper to control established tumors .
-
This technology enables scar-free breast reconstruction and restores the feeling of the breast area!
Time of Update: 2022-01-23
The aim of this study is to propose a breast reconstruction method that utilizes the principles of power-assisted liposuction and lipofilling (PALL) for breast matrix separation by infiltration, tunnelling, extensive destruction and fat augmentation, combined with ring (PALLL) Recruit a vascularized flap to reshape the breast .
-
The fertility hope of gynecological cancer patients, you need to know these
Time of Update: 2022-01-23
In recent years, with the younger age of onset of malignant tumors and the general postponement of the reproductive age of women, fertility protection has become a difficult problem that often needs to be weighed and solved when clinically formulating treatment plans for cancer patients .
-
Bosn J Basic Med Sci: Beware of Chronic Mechanical Stimulation, May Induce Oral Squamous Cell Carcinoma!
Time of Update: 2022-01-23
A study published in Bosn J Basic Med Sci qualitatively and quantitatively reviewed the relationship between chronic mechanical stimulation and OSCC .
, Chronic mechanical irritation and oral squamous cell carcinoma: A systematic review and meta-analysis .
-
Radiology: Dual-energy CT perfusion, making imaging at the forefront of non-small cell lung cancer evaluation!
Time of Update: 2022-01-23
Several recently published studies have shown that dual-energy CT can obtain mean iodine concentration measurements throughout the tumor volume to predict the effect of tumor chemotherapy and further reflect its relationship with postoperative prognosis .
-
J Clin Invest: MEK inhibitor cobimetinib combined with PD-L1 inhibitor atezolizumab prolongs PFS in biliary tract cancer (BTC)
Time of Update: 2022-01-23
The study showed that atezolizumab + cobimetinib combination therapy prolonged PFS compared with atezolizumab monotherapy, but the low response rates in both groups also indicated the immune- tolerant properties of BTC .
-
Nature Chemical Biology: Crazy Idea: Arming CAR-T Cells to Become a 'Micro Pharmacy' for Cancer Drugs
Time of Update: 2022-01-23
Scheinberg, corresponding author of the study, said: "We call the engineered cells SEAKER cells, SEAKER stands for Synthetic Enzyme-Armed KillER cells, which not only enhance the targeting ability of CAR-T cells, but also combine local Effective small molecule anticancer drugs minimize accidental injury and achieve dual effects .
